Beat Bornhauser Department of Oncology and Children’s Research Center, University Children's Hospital Zurich, Switzerland
1 protocol

Jean-Pierre Bourquin Department of Oncology and Children’s Research Center, University Children’s Hospital Zurich, Switzerland
1 protocol

Adriano Aguzzi Institute of Neuropathology, University Hospital of Zurich, Switzerland
1 protocol

Pawel Pelczar Institute of Laboratory Animal Science, University of Zurich, Switzerland
1 protocol
mohan babu Stanford University
3 protocols

Ruth Franklin Yale University
15 protocols

Saskia Erttmann Umeå University
7 protocols

Scott McComb
  • Research scientist, National Research Council of Canada, Human Health and Thereapeutics Research Centre
Research focus
  • Immunology
  • CAR-T, cancer immunology, cell death
  • 1 Author merit


PhD, University of Ottawa, 2013

Lab information

The Scott McComb lab focuses on research into chimeric antigen receptor T cells (CAR-T), genome editing (CRISPR and other technologies), and the mechanisms of cell death. CAR-T is an exciting new avenue to redirect immune cells to target and kill cancer. While breakthroughs in CAR-T therapy have led to life-saving treatments for patients with previously incurable leukemia, such therapies have been less successful against solid tumours. Moreover, the determinants of long term cancer regression in CAR-T treated patients are not yet well understood. Using genome editing, we are dissecting the mechanisms of programmed cell death and other immune signalling pathways in T cells in order to improve their effectiveness against cancer.


1 Protocol published
CRISPR-Cas9 based knockout strategies are increasingly used to analyze gene function. However, redundancies and overlapping functions in biological signaling pathways can call for generating multi-gene knockout cells, which remains a relatively ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.